Off-label transcranial magnetic stimulation in amnestic mild cognitive impairment and Alzheimer's disease: A twelve-year case series in a single clinic

Brain Stimul. 2021 Jul-Aug;14(4):751-753. doi: 10.1016/j.brs.2021.05.001. Epub 2021 May 8.

Authors

Robert A Tumasian 3rd¹, Gayatri Devi²

Affiliations

¹ Park Avenue Neurology, United States; Columbia University Department of Biostatistics, United States.
² Park Avenue Neurology, United States; SUNY Downstate Department of Neurology, United States; Lenox Hill Hospital, Northwell Health Departments of Neurology & Psychiatry, United States. Electronic address: gd@nybrain.org.

PMID: 33971328
DOI: 10.1016/j.brs.2021.05.001

No abstract available

Keywords: Alzheimer's disease treatment; Language; Long-term efficacy; Long-term safety; Transcranial magnetic stimulation (TMS).

Publication types

Letter

MeSH terms

Alzheimer Disease* / therapy
Cognitive Dysfunction* / therapy
Humans
Off-Label Use
Transcranial Magnetic Stimulation

Grants and funding

U01 AG016976/AG/NIA NIH HHS/United States